Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $4.6 million.

  • Viridian Therapeutics, Inc.\DE's Change in Accured Expenses rose 1807.48% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 6113.5%. This contributed to the annual value of $21.6 million for FY2024, which is 33163.67% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Change in Accured Expenses of $4.6 million as of Q3 2025, which was up 1807.48% from $6.1 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Change in Accured Expenses registered a high of $11.1 million during Q4 2024, and its lowest value of -$15.8 million during Q1 2025.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Change in Accured Expenses had a median value of $2.6 million in 2023 and averaged $1.6 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Change in Accured Expenses soared by 161077.84% in 2021, and later plummeted by 167102.91% in 2025.
  • Viridian Therapeutics, Inc.\DE's Change in Accured Expenses (Quarter) stood at $1.6 million in 2021, then surged by 269.25% to $6.0 million in 2022, then decreased by 19.69% to $4.8 million in 2023, then skyrocketed by 129.8% to $11.1 million in 2024, then tumbled by 58.38% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $6.1 million for Q2 2025, and -$15.8 million during Q1 2025.